The development of new drugs for the treatment of cancer is an important objective of many pharmaceutical companies, biotech companies and academic research institutes. The process of developing new anticancer agents is distinctly different from drug development in many other therapeutic areas. This intensive training course is primarily designed to provide participants with specific knowledge on the preclinical and clinical development of new agents intended for the treatment of cancer, in particular in Europe. The course will also address strategic, regulatory and scientific issues in the development of such agents. Successful anticancer drug development requires basic understanding of tumor (molecular) biology and cancer patient management. Therefore, part of the educational program is devoted to tumor biology, pathology and clinical management of patients with cancer. The latter will be illustrated by expert reviews of breast cancer, lung cancer, and hematological malignancies.

CLICK HERE TO DOWNLOAD THE COURSE FLYER OF OUR 2009 COURSE

CLIK HERE FOR THE EDUCATIONAL SCHEDULE OF OUR 2009 COURSE (UPDATED NOVEMBER 13, 2009).

If you are interested in participating in the 2010 training course, please contact course management with your contact details. You will then receive the complete information on the 2010 course when it becomes available.

Course management and information
MCCM Meeting Management BV
P.O. Box 77
3480 DB Harmelen
The Netherlands 
Tel: +31 (0)88-089 8100
Fax: +31 (0)88-089 8109
Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it